Antimicrobial Agent Targeting Resistant CF Infections Named ‘Orphan Drug’ by FDA
Cystic Fibrosis, News
TGV-Inhalonix, Inc., recently announced that its drug candidate, the antimicrobial agent Mul-1867, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of antibiotic-resistant bacterial ... Read more